Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations
- PMID: 9362242
- DOI: 10.1152/ajpheart.1997.273.4.H1769
Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations
Abstract
The current study examined the contributions of angiotensin-converting enzyme (ACE) vs. chymase to angiotensin II (ANG II) generation in membrane preparations from left ventricles of humans, dogs, rabbits, and rats and from total heart of mice. ACE and chymase activity were measured in membrane preparations extracted with low or high detergent (LD and HD, respectively) concentrations. We hypothesized that ACE, which is membrane bound in vivo, would be preferentially localized to the HD preparation, whereas chymase, which is localized to the cytoplasm and cardiac interstitium, would be localized to the LD preparation. In human heart, ACE activity was 16-fold higher in the HD than in the LD preparation, whereas chymase activity was 15-fold higher in the LD than in the HD preparation. Total ANG II formation was greater in human heart [15.8 +/- 3.4 (SE) micromol ANG II x g(-1) x min(-1)] than in dog, rat, rabbit, and mouse hearts (3.90 +/- 0.35, 0.41 +/- 0.02, 0.61 +/- 0.07, and 1.16 +/- 0.08 micromol ANG II x g(-1) x min(-1), respectively, P < 0.05, by analysis of variance). ANG II formation from ACE was higher in mouse heart (1.09 +/- 0.05 micromol ANG II x g(-1) x min(-1), p < 0.001) than in rabbit, human, dog, and rat hearts (0.55 +/- 0.06, 0.34 +/- 0.01, 0.32 +/- 0.06, and 0.31 +/- 0.02 micromol ANG II x g(-1) x min(-1), respectively). In contrast, chymase activity was higher in human heart (15.3 +/- 3.4 micromol ANG II x g(-1) x min(-1)) than in dog, rat, rabbit, and mouse hearts (3.59 +/- 0.29, 0.10 +/- 0.01, 0.06 +/- 0.01, and 0.07 +/- 0.01 micromol ANG II x g(-1) x min(-1), respectively). Our results demonstrate important species differences in the pathways of intracardiac ANG II generation. Chymase predominated over ACE activity in human heart, accounting for extremely high total ANG II formation in human heart compared with dog, rat, rabbit, and mouse hearts.
Similar articles
-
Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation.Am J Physiol. 1995 Dec;269(6 Pt 2):H2065-73. doi: 10.1152/ajpheart.1995.269.6.H2065. Am J Physiol. 1995. PMID: 8594918
-
Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme.Biochem Biophys Res Commun. 2016 Sep 16;478(2):559-64. doi: 10.1016/j.bbrc.2016.07.100. Epub 2016 Jul 25. Biochem Biophys Res Commun. 2016. PMID: 27465904 Free PMC article.
-
Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity.Circulation. 1997 Mar 18;95(6):1455-63. doi: 10.1161/01.cir.95.6.1455. Circulation. 1997. PMID: 9118513
-
Cardiac angiotensin II formation: the angiotensin-I converting enzyme and human chymase.Eur Heart J. 1993 Nov;14 Suppl I:177-82. Eur Heart J. 1993. PMID: 8293772 Review.
-
[Angiotensin II formation by chymase in the cardiovascular tissue].Nihon Yakurigaku Zasshi. 1998 Sep;112(3):203-12. doi: 10.1254/fpj.112.203. Nihon Yakurigaku Zasshi. 1998. PMID: 9793075 Review. Japanese.
Cited by
-
Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: evidence for and against the combination in the treatment of hypertension and proteinuria.Curr Hypertens Rep. 2002 Oct;4(5):394-402. doi: 10.1007/s11906-002-0070-x. Curr Hypertens Rep. 2002. PMID: 12217259 Review.
-
Is chymase 1 a therapeutic target in cardiovascular disease?Expert Opin Ther Targets. 2023 Jul-Dec;27(8):645-656. doi: 10.1080/14728222.2023.2247561. Epub 2023 Aug 21. Expert Opin Ther Targets. 2023. PMID: 37565266 Free PMC article. Review.
-
Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation.PLoS One. 2013;8(3):e60827. doi: 10.1371/journal.pone.0060827. Epub 2013 Mar 29. PLoS One. 2013. Retraction in: PLoS One. 2024 Jun 11;19(6):e0305584. doi: 10.1371/journal.pone.0305584. PMID: 23556005 Free PMC article. Retracted.
-
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status.Br J Pharmacol. 2010 Jul;160(6):1273-92. doi: 10.1111/j.1476-5381.2010.00750.x. Br J Pharmacol. 2010. PMID: 20590619 Free PMC article. Review.
-
Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practice.J Clin Hypertens (Greenwich). 2003 Nov-Dec;5(6):414-20. doi: 10.1111/j.1524-6175.2003.02836.x. J Clin Hypertens (Greenwich). 2003. PMID: 14688498 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous